|
We are proud to announce the US launch of our molecular diagnostic test, the T2SARS-CoV-2 Panel, which has demonstrated excellent clinical performance. Adding this test to our existing sepsis-related portfolio illustrates our commitment to transformative diagnostics that improve the lives of patients,” said John Sperzel, President and Chief Executive Officer of T2 Biosystems. “Given the susceptibility of critically-ill COVID-19 patients to develop bacterial or fungal co-infections and secondary infections that can lead to sepsis, we believe our platform can be used to identify acute COVID-19 infections, and optimize outcomes for patients under intensive care Nach dem letzten Absatz steht die Genehmigung im beantragten Dringlichkeitsfall noch aus. Man ist auslieferugsbereit aber die FDA fehlt noch. |
|
| aus der Diskussion: | T2 biosystems der game changer?! |
| Autor (Datum des Eintrages): | gordoncamelion (03.07.20 09:58:11) |
| Beitrag: | 324 von 1,897 (ID:64279441) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |